knowledge -WSS

knowledge

author：hotspot 2025-09-03 12:11:16 - browse：3648

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： AI can decode, harness the power of the humane immune system

focus

WSS

Why does health care cost so much? A reading guide

When women are denied an abortion, their children fare worse than peers

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Cell therapy fails to slow type 1 diabetes, but safety is established

Cell therapy fails to slow type 1 diabetes, but safety is established

Cancer researcher Catriona Jamieson is sending tumors into space

hotspot

knowledge

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Why Charlie Gard's case is so disturbing to Americans

As demand for Covid shots wanes, Moderna seeks its next success

What to expect at HLTH 2023, the health care industry conference

Duchenne breakthrough therapy leaves behind pioneering families

3 questions for the future of Biden's cancer moonshot

Novavax promises a turnaround & Lilly roils the obesity market

Key Senate committee drafts bipartisan bill to stem drug shortages

New air purifier tech could be key to improving indoor air quality

Bill would stop addiction treatment from triggering child abuse inquiry

leisure time

Key Senate committee drafts bipartisan bill to stem drug shortages

Why age limits for politicians are a terrible idea

Melinda French Gates resigns from Gates Foundation

Bird flu in milk supply is likely coming from asymptomatic cows

3 questions for the future of Biden's cancer moonshot

Melinda French Gates resigns from Gates Foundation

explore

hotspot

focus

explore